reports
Antibe Therapeutics Announces Closing of $28.75 Million Bought Deal Of...
Toronto, Ontario--(Newsfile Corp. - June 30, 2020) - Antibe Therapeutics Inc. (TSXV: ATE) ("Antibe" or the "Company") announced that it closed its previously announced bought deal public offering of 62,500,000 units of the Company (the "Units") at a price of $0.40 per Unit (the "Offering Price") plus the exercise in full of the Underwriters' over-allotment option of 9,375,000 units for aggregate gross proceeds of $28,750,000 (the "Offering"). The Offering was made pursuant to an underwriting agreement dated June 15, 2020 with a syndicate of underwriters led by Bloom Burton Securities Inc., tog...
- Pooya Hemami
Antibe Therapeutics - Working towards a GI-safe NSAID drug
Antibe’s lead drug, ATB-346, combines a hydrogen sulfide (H2S)-emitting molecule with naproxen, an off-patent non-steroidal anti-inflammatory drug (NSAID). The firm plans to start a double-blinded Phase IIb osteoarthritis (OA) study in July 2018, with data expected in Q418. The trial’s efficacy results can build on recent Phase IIb gastrointestinal (GI) safety data and position Antibe well to seek ATB-346 partnerships or out-licensing deals.
Antibe Therapeutics to Present at Bloom Burton & Co. Healthcare Invest...
TORONTO--(BUSINESS WIRE)-- Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF) is pleased to announce that it will be presenting at the upcoming Bloom Burton & Co. Healthcare Investor Conference being held on May 2 – 3, 2018 in Toronto, Canada. Event: Seventh Annual Bloom Burton & Co. Healthcare Investor ConferenceLocation: Hall B, Lower Concourse Level, Sheraton Centre Toronto Hotel (Toronto, Canada)Date: Wednesday, May 2nd, 2018Time: 3:00 pm (ET) Antibe’s CEO, Dan Legault, will del...
Antibe Therapeutics Announces CEO Letter to Shareholders
TORONTO--(BUSINESS WIRE)-- Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF): To our stakeholders, The recent success of our lead drug, ATB-346, in its Phase 2B gastrointestinal (“GI”) safety clinical study was a significant milestone for Antibe and represented a major inflection point in our value. Furthermore, we are now one clinical study away from the strategic monetization of our drug platform for the major markets. With such an important and exciting time ahead of us, we thought this would be an ideal o...
Antibe Therapeutics Provides Financial Update
TORONTO--(BUSINESS WIRE)-- Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV:ATE, OTCQB:ATBPF), a leader in developing safer therapeutics for pain and inflammation that recently announced a successful Phase 2B clinical trial demonstrating the gastrointestinal safety of its lead drug, reports that the Company now has a significantly augmented balance sheet. Augmented cash position from warrant exercises In the period since January 1st, 2018, Antibe has received proceeds of approximately $4 million from warran...
Antibe Therapeutics Announces Successful Phase 2B Gastrointestinal Saf...
TORONTO--(BUSINESS WIRE)-- Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF) is pleased to announce that its lead drug, ATB-346, met its primary endpoint in the Phase 2B gastrointestinal (“GI”) safety study. The double-blind study was conducted in 244 healthy volunteers and was designed to demonstrate the superiority of ATB-346 in GI safety compared to naproxen, the most prescribed nonsteroidal anti-inflammatory drug (“NSAID”) in the USA. Subjects on ATB-346 exhibited an ulceration rate of 2.5% versus an u...
Antibe Therapeutics Announces No Material Change
TORONTO--(BUSINESS WIRE)-- Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF) wishes to advise that it is not aware of any undisclosed material change in the Company’s activities that would account for recent market activity. As previously disclosed in its February 26th, 2018 press release, the Company anticipates being in a position to report top-line results of the Phase 2b clinical trial of its lead drug, ATB-346, during the week of March 19th, 2018. About Antibe Therapeutics Inc.Antibe develops...
Antibe Therapeutics Reports Q3 2018 Interim Financial and Operating Re...
TORONTO--(BUSINESS WIRE)-- Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Tuesday, February 27th for the fiscal quarter ended December 31, 2017. The Company’s unaudited fiscal Q3 2018 condensed interim consolidated financial statements and MD&A are available on SEDAR. In addition, the Company has granted BND Projects Inc. 36,000 options for investor relations services. Each option has an exercise price of $0.29, being the 5-day volume weighted averag...
Antibe Therapeutics Provides Update on Phase 2B Gastrointestinal Safet...
TORONTO--(BUSINESS WIRE)-- Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF) would like to confirm the previously announced timing for its Phase 2B double-blind clinical trial of ATB-346. The final subject has now completed treatment and the subsequent two-week monitoring period. The CRO conducting the study, Topstone Research Inc. (“Topstone”), is currently performing data validation and analysis. Antibe remains on its previously announced schedule and anticipates being in a position to report top-line re...
Antibe Therapeutics Announces Enrollment of Final Subjects in Phase 2B...
TORONTO--(BUSINESS WIRE)-- Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a diversified biotechnology company with two best-in-class divisions in pain/inflammation and regenerative medicine, is pleased to announce that the final subjects have been enrolled and are on treatment in the key Phase 2B double-blind clinical trial of ATB-346. The study is being conducted in 240 healthy volunteers and is designed to demonstrate the unequivocal superiority of ATB-346 in gastrointestinal (“GI”) safety compared t...
Antibe Therapeutics Engages Brand Institute to Advise on Nonproprietar...
TORONTO--(BUSINESS WIRE)-- Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV:ATE, OTCQB:ATBPF) is pleased to announce that it has engaged Brand Institute, Inc. (“Brand Institute”) to advise on the nonproprietary name for its lead drug candidate, ATB-346. Every approved pharmaceutical drug is required to establish an unambiguous international name that is derived from standardized naming conventions to avoid prescription errors. The nonproprietary naming process is governed globally by the International Nonproprietary...
Antibe Therapeutics Reports Q2 2018 Interim Financial and Operating Re...
TORONTO--(BUSINESS WIRE)-- Antibe Therapeutics Inc. ("Antibe") (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Tuesday, November 28th for the fiscal quarter ended September 30, 2017. The Corporation’s unaudited fiscal Q2 2018 condensed interim consolidated financial statements and MD&A are available on SEDAR. Dan Legault, Antibe’s CEO, commented, “Our most recently completed fiscal quarter represented a significant milestone for Antibe as our lead drug, ATB-346, commenced its key Phase 2b clinical study...
Antibe Therapeutics Announces Key US Distribution Partnership for Its ...
TORONTO--(BUSINESS WIRE)-- Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF) is pleased to announce that its subsidiary, Citagenix Inc. (“Citagenix”), has been selected by Darby Dental Supply, LLC (“Darby Dental”) to be its supplier of premium bone grafting and tissue regeneration products. Darby Dental has been in operation for nearly 70 years and has established itself as one of the largest and most trusted dental distributors in the United States. Liz Meyers, Vice President of Marketing & Purch...
Antibe Therapeutics to Attend 2017 CPhI Worldwide Conference to Contin...
TORONTO--(BUSINESS WIRE)-- Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF) will be attending the 2017 CPhI Worldwide conference next week in Frankfurt, Germany. CPhI Worldwide is the world’s largest pharma trade show and considered the leading international pharmaceutical business and networking event. The event will be held on October 24th – 26th and will host over 42,000 pharma industry professionals from over 150 countries. Antibe will be meeting with several regional pharmaceutical companies...
Antibe Therapeutics Announces Enrollment of First Subjects in Phase 2B...
TORONTO--(BUSINESS WIRE)-- Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQX: ATBPF), is pleased to announce that the first eight subjects have been enrolled and are on treatment in its key Phase 2B clinical trial, a double-blind, gastrointestinal (“GI”) safety study in 240 subjects with naproxen as a comparator. Naproxen is the most prescribed nonsteroidal anti-inflammatory drug (“NSAID”) in the USA. The study is designed to demonstrate the unequivocal superiority of ATB-346 in GI safety. Antibe’s CEO, D...
Antibe Therapeutics Reports Q1 2018 Interim Financial and Operating Re...
TORONTO--(BUSINESS WIRE)-- Antibe Therapeutics Inc. ("Antibe") (TSXV:ATE) (OTCQX:ATBPF) filed its financial and operating results on Tuesday, August 29th for the fiscal quarter ended June 30, 2017. The Corporation’s unaudited fiscal Q1 2018 condensed interim consolidated financial statements and MD&A are available on SEDAR. Dan Legault, Antibe’s CEO, commented, “The successful completion of our brokered financing was a significant achievement this quarter, raising $5 million in gross proceeds that fully funds the key Phase 2b...
Antibe Therapeutics Inc. Announces Closing of Public Offering
TORONTO--(BUSINESS WIRE)-- Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE) (OTCQX: ATBPF) a diversified biotechnology company announced today the second and final closing of its previously announced marketed public offering of units (the “Units”) for additional gross proceeds of approximately $933,000 (the “Offering”). In total, the Company has raised gross proceeds of $4,983,000 from the sale of 49,830,000 Units. The Company issued 9,330,000 Units at a price of $0.10 per Unit. Each Unit is comprised o...
Antibe Therapeutics Receives Approval to Initiate Phase 2 Gastrointest...
TORONTO--(BUSINESS WIRE)-- Antibe Therapeutics Inc. ("Antibe") (TSXV: ATE, OTCQX: ATBPF) is pleased to announce that it has received approval from Health Canada to initiate a Phase 2, double-blind, gastrointestinal endoscopy trial. The study will involve a total of 240 healthy volunteers, who will be randomized to one of two groups. One group will be treated for 14 days with Antibe’s lead drug, ATB-346 (250 mg once daily), while the other group will be treated for 14 days with the standard prescription dose of naproxen (500 mg twice d...
Antibe Therapeutics Reports 2017 Year-End Financial and Operating Resu...
TORONTO--(BUSINESS WIRE)-- Antibe Therapeutics Inc. ("Antibe") (TSXV: ATE, OTCQX: ATBPF) filed its financial and operating results Friday, July 28 for the fourth quarter and the year ended March 31, 2017. The Corporation's audited 2017 financial statements, MD&A and AIF are available on SEDAR. About Antibe Therapeutics Inc. Antibe develops safer medicines for pain and inflammation. Antibe’s technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine. ...
Antibe Therapeutics Inc. Announces Closing of Public Offering
TORONTO--(BUSINESS WIRE)-- Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE) (OTCQX: ATBPF) a diversified biotechnology company announced today the first closing of its previously announced marketed public offering of units (the “Units”) for gross proceeds of approximately $4,050,000 (the “Offering”). The Company issued 40,498,999 Units at a price of $0.10 per Unit. Each Unit is comprised of one common share of the Company (a “Common Share”) and one-half of one Common Share purchase warrant (each whole warrant,...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.